ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

トルテロジン

Tolterodine

HCID 443879
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
124937-51-5
標準SMILES
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1
InChIKey
OOGJQPCLVADCPB-HXUWFJFHSA-N
分子式
C22H31NO
平均分子量
325.5 g/mol
単同位体質量
325.24056461

概要

Tolterodine is a tertiary amine. It has a role as a muscarinic antagonist, a muscle relaxant and an antispasmodic drug. It is functionally related to a p-cresol.

名称と識別子

優先名称
Tolterodine
IUPAC
2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
現地名
トルテロジン
英語名
Tolterodine
分子式
C22H31NO
分子量
325.49

名称と別名

tolterodine124937-51-5(+)-TolterodineTolterodinumKabi 2234TolterodinaKabi-22342-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenolWHE7A56U7K(+)-(R)-2-(alpha-(2-(Diisopropylamino)ethyl)benzyl)-p-cresolCHEBI:96222-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
名称をさらに表示
トルテロジンR-(+)-トルテロジントルテロジン酒石酸塩2-[(1R)-3-[ビス(1-メチルエチル)アミノ]-1-フェニルプロピル]-4-メチルフェノール(+)-トルテロジン2-[(1R)-1-フェニル-3-(ジイソプロピルアミノ)プロピル]-4-メチルフェノール(R)-トルテロジン2-[(R)-1-フェニル-3-(ジイソプロピルアミノ)プロピル]-4-メチルフェノール2-[(1R)-3-[ビス(プロパン-2-イル)アミノ]-1-フェニルプロピル]-4-メチルフェノール4-メチル-2-[(R)-3-(ジイソプロピルアミノ)-1-フェニルプロピル]フェノールトロテロジンDETROLTOLTERODINE L-TARTRATEPNU-20058EDETRUSITOLPNU 200583Tolterodine-d6TolterodineBaseTolterodine-d14
Detrusitol xlEfflosomyl xlMariosea xlPreblacon xlSantizor xl2-((1R)-3-(bis(propan-2-yl)amino)-1-phenylpropyl)-4-methylphenol2-((1R)-3-(di(propan-2-yl)amino)-1-phenylpropyl)-4-methylphenol2-[(1R)-3-(di(propan-2-yl)amino)-1-phenylpropyl]-4-methylphenol

物性

構造計算による物性

XLogP
5.6
極性表面積
23.5 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
7
重原子数
24
形式電荷
0
複雑度
340

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP5.6
Solubility5.34e-03 g/L
Human DrugsBreast Feeding; Lactation; Milk, Human; Muscarinic Antagonists; Parasympatholytics
Endocrine DisruptorsPotential endocrine disrupting compound
Physical DescriptionSolid
Dissociation Constants9.8
Collision Cross Section182.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

比旋光度
25 · D25 +72° (c = 1.0 in CH2Cl2)
沸点
442.2 · 442.2±45.0 °C(Predicted)
比重(密度)
1.003 · 1.003±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · -20°C Freezer

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 3 (100%)

毒性情報

Hepatotoxicity · 1 件

In multiple randomized controlled trials of tolterodine in patients with overactive bladder syndrome, serum aminotransferase and alkaline phosphatase elevations were not common, arising in less than 1% of treated subjects and in a similar proportion of placebo recipients. In these clinical trials there were no reports of clinically apparent liver injury or jaundice. Since the approval of tolterodine in 1998 and its widescale use (with more than 1 million prescriptions filled yearly in the United States), there has been only one published case report of liver injury with symptoms and jaundice attributed to its use (Case 1). Thus, acute symptomatic liver injury due to tolterodine must be very rare, if it occurs at all.

Adverse EffectsAdverse effects of tolterodine are significantly lower than that of other antimuscarinic drugs indicated for the same use.
Toxicity Summary · 1 件

To prevent toxicity, patients with hepatic impairment should be given a lower dose since the drug's elimination is lower than that of healthy patients. Additionally, tolterodine demonstrated higher concentrations in patients with renal impairment. Therefore, recommendations include a decrease in drug dosage in both patients with hepatic or renal impairment.

化学と産業

薬理情報

ATC Code · 3 件

G04BD07

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein BindingApproximately 96.3%.
Pharmacodynamics · 1 件

Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. Tolterodine has a pronounced effect on bladder function. The main effects of tolterodine are an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure, consistent with an antimuscarinic action on the lower urinary tract.

Mechanism of Action · 1 件

Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.

Biological Half-Life1.9-3.7 hours
Metabolism/MetabolitesTolterodine has known human metabolites that include 5-Hydroxymethyl tolterodine and N-Dealkylated tolterodine.
FDA Pharmacological Classification · 6 件

WHE7A56U7K

TOLTERODINE

Established Pharmacologic Class [EPC] - Cholinergic Muscarinic Antagonist

Mechanisms of Action [MoA] - Cholinergic Muscarinic Antagonists

関連反応

26 件
反応記録を作成
HRID 29228 の反応式
HRID 29228生成物として
HRID 217309 の反応式
HRID 217309生成物として
HRID 237179 の反応式
HRID 237179生成物として
HRID 384425 の反応式
HRID 384425反応物として
HRID 384426 の反応式
HRID 384426反応物として
HRID 384427 の反応式
HRID 384427反応物として
HRID 384428 の反応式
HRID 384428反応物として
HRID 384429 の反応式
HRID 384429反応物として
前へ1 / 4 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
124937-51-5
PubChem CID
443879
DTXSID
DTXSID3023687
ChEMBL
CHEMBL1382
ChEBI
CHEBI:9622
UNII
WHE7A56U7K
EC Number
805-304-4
Nikkaji
J561.859B
溶解性
20 mg/mL以上 · DMSO:20mg/mL以上
酸解離定数(Pka)
9.8 · pKa 9.8 (Uncertain)
外見
粉
色
ホワイトからオフホワイト
CAS データベース
124937 · 124937-51-5(CAS DataBase Reference)

化学的性質

化学的特性Pale Yellow Gel

Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

tolterodine

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
risk_code
63-51/53
hazard_code
Xn,N
safety_code
22-36/37-57

Tolterodine is a Cholinergic Muscarinic Antagonist. The mechanism of action of tolterodine is as a Cholinergic Muscarinic Antagonist.

TOLTERODINE

MeSH Pharmacological Classification · 2 件

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

Absorption, Distribution and Excretion · 2 件

Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.

113 ± 26.7 L

Cellular LocationsMembrane

用途と製造

UsesUse (kg; approx.) in Germany (2009): >50
応用分野 · 2 件

使用A muscarinic receptor antagonist. Used in the treatment of urinary incontinence.

一般的な説明Tolterodine (Detrol), 2-[3-[bis(1-methylethyl)amino]-1-phenyl-propyl]-4-methyl-phenol, is an antimuscarinicagent that acts on M2 and M3 muscarinic subtypereceptors. By competitively blocking of the muscarinicreceptors results in a reduction of the smooth muscle tone,allowing for greater volume of urine to be stored in the bladder.This results in less urinary incontinence, urgency, andfrequency.

上流・下流製品情報

上流原料

p-クレゾールオルメロキシフェンLauric acidイソプロピルアルコール硫酸水素塩酸水酸化ナトリウム水素化ジイソブチルアルミニウム水酸化パラジウム / 炭素桂皮酸ジイソプロピルアミンtrans-けい皮酸L-(+)-酒石酸炭酸カリウム炭酸ナトリウムくえん酸